Lymphoma News and Research RSS Feed - Lymphoma News and Research

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.
New online tool helps educate practicing oncologists with therapeutic decision-making for NSCLC

New online tool helps educate practicing oncologists with therapeutic decision-making for NSCLC

A new interactive online tool helps educate practicing oncologists worldwide with therapeutic decision-making for advanced non-small cell lung cancer (NSCLC) based on a patient's molecular and clinical characteristics by providing feedback from an expert panel. [More]
Researchers identify first genetic variation linked to increased risk of peripheral neuropathy

Researchers identify first genetic variation linked to increased risk of peripheral neuropathy

Researchers have identified the first genetic variation that is associated with increased risk and severity of peripheral neuropathy following treatment with a widely used anti-cancer drug. Investigators also found evidence of how it may be possible to protect young leukemia patients without jeopardizing cures. [More]
Study helps solve mystery about how genetic variations can increase cancer risk

Study helps solve mystery about how genetic variations can increase cancer risk

Single-letter genetic variations within parts of the genome once dismissed as 'junk DNA' can increase cancer risk through wormhole-like effects on far-off genes, new research shows. [More]
TKI introduction improves French CML patient survival

TKI introduction improves French CML patient survival

Real-world study findings from France show the significant impact tyrosine kinase inhibitor treatment has had on the survival of patients with Philadelphia chromosome-positive chronic myeloid leukaemia. [More]
Hospira announces launch of first biosimilar monoclonal antibody in Europe

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Hospira, Inc., a world leader in the development of biosimilar therapies, today announced the launch of the first biosimilar monoclonal antibody (mAb), Inflectra (infliximab), in major European markets. [More]
Young adult survivors of leukemia and lymphoma report high distress than older survivors

Young adult survivors of leukemia and lymphoma report high distress than older survivors

Two University of Colorado Cancer Center studies published in the Journal of Psychosocial Oncology show that young adult survivors (ages 18-39) of leukemia and lymphoma are more likely to report high distress than older survivors (ages 65+). [More]
Leukemia & Lymphoma Society announces launch of new partnership to empower people with lymphoma

Leukemia & Lymphoma Society announces launch of new partnership to empower people with lymphoma

The Leukemia & Lymphoma Society together with the Lymphoma Research Foundation, CancerCare, the Association of Community Cancer Centers and Genentech announced the launch of a new partnership, the Alliance for Resource Collaboration in Hematology (ARCH). [More]
Chemotherapy or immunosuppressive treatment may reactivate HBV

Chemotherapy or immunosuppressive treatment may reactivate HBV

Individuals previously infected with the hepatitis B virus (HBV) who receive chemotherapy or immunosuppressive treatment may be at risk of reactivating the disease according to a summary of report from the Emerging Trends Conference, "Reactivation of Hepatitis B," and published in Hepatology, a journal of the American Association for the Study of Liver Diseases. [More]

Breakthrough therapies for blood cancers may provide reasonable value for money spent

Amid the growing debate about the high price of powerful new drugs in the United States, a recent analysis suggests that breakthrough therapies for blood cancers may, in many cases and with some important caveats, provide reasonable value for money spent. [More]

Breakthrough blood cancer therapies may provide reasonable value for money spent

Amid the growing debate about the high price of powerful new drugs in the United States, a recent analysis suggests that breakthrough therapies for blood cancers may, in many cases and with some important caveats, provide reasonable value for money spent. [More]
Study focuses on two natural approaches to preventing breast cancer

Study focuses on two natural approaches to preventing breast cancer

Preventing cancer requires intimate knowledge of how cancer starts, what causes it to grow and flourish, and how to stop it in its tracks. Sometimes this comes in the form of a vaccine (the HPV vaccine for cervical and head and neck cancers), a screening (a colonoscopy for colorectal cancer) or a blood test (the PSA level test for prostate cancer). [More]
Anti-viral immune cells could inhibit bone marrow transplant infections caused by CMV

Anti-viral immune cells could inhibit bone marrow transplant infections caused by CMV

Bone marrow transplantation is a life-saving therapy for patients with blood cancers like leukemia or lymphoma. However, the depletion of the patient's immune system prior to transplantation can put patients at risk of for an infection by a virus called cytomegalovirus (CMV) that can be life threatening in these immune-compromised individuals. [More]
Multiplexed testing for EGFR and ALK gene rearrangements may be cost-effective for NSCLC treatment

Multiplexed testing for EGFR and ALK gene rearrangements may be cost-effective for NSCLC treatment

Multiplexed genetic screening for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements and subsequent biomarker-guided treatment is cost-effective compared with standard chemotherapy treatment without any molecular testing in the metastatic non-small cell lung cancer (NSCLC) setting in the United States. [More]
FDA’s approval of ibrutinib to treat Waldenstrom's macroglobulinemia receives praises from LLS

FDA’s approval of ibrutinib to treat Waldenstrom's macroglobulinemia receives praises from LLS

The U.S. Food and Drug Administration approval of ibrutinib (Imbruvica) to treat patients with Waldenstrom's macroglobulinemia(WM) is a significant advance for patients with this rare blood cancer. [More]
Breast and lung cancer patients with low levels of TTP protein have poorer prognosis

Breast and lung cancer patients with low levels of TTP protein have poorer prognosis

Moffitt Cancer Center researchers have found that breast and lung cancer patients who have low levels of a protein called tristetraprolin (TTP) have more aggressive tumors and a poorer prognosis than those with high levels of the protein. [More]
Alectinib active against leptomeningeal metastases in ALK-positive NSCLC

Alectinib active against leptomeningeal metastases in ALK-positive NSCLC

Patients with anaplastic lymphoma kinase-rearranged non-small-cell lung cancer who have leptomeningeal metastases may benefit from treatment with the second-generation ALK inhibitor alectinib, a case series suggests. [More]
Manchester researcher discover novel way to eradicate cancer stem cells

Manchester researcher discover novel way to eradicate cancer stem cells

A way to eradicate cancer stem cells, using the side-effects of commonly used antibiotics, has been discovered by a University of Manchester researcher following a conversation with his young daughter. [More]
New study focuses on improving Iowa healthcare exchange

New study focuses on improving Iowa healthcare exchange

The Partnership to Fight Chronic Disease released a public opinion poll of Iowa health care leaders and a new study analyzing the impact of increased cost sharing on patient adherence to prescription medications. The PFCD is a nationwide coalition working to educate policy makers and the public on the costs of chronic diseases. [More]
ASCO announces cancer Advance of the Year

ASCO announces cancer Advance of the Year

The American Society of Clinical Oncology for the first time announced its cancer Advance of the Year: the transformation of treatment for the most common form of adult leukemia. Until now, many patients with chronic lymphocytic leukemia (CLL) have had few effective treatment options. Four newly approved therapies, however, are poised to dramatically improve the outlook for patients with the disease. [More]
Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson today announced sales of $18.3 billion for the fourth quarter of 2014, a decrease of 0.6% as compared to the fourth quarter of 2013. Operational results increased 3.9% and the negative impact of currency was 4.5%. Domestic sales increased 7.4%. [More]